Compound News and Research

RSS
Excella achieves SafeBridge Potent Compound Safety Certification

Excella achieves SafeBridge Potent Compound Safety Certification

Researcher identifies substance that inhibits cancer growth by activating 'dark genome'

Researcher identifies substance that inhibits cancer growth by activating 'dark genome'

EPO grants three core patents to caprotec's CCMS technology

EPO grants three core patents to caprotec's CCMS technology

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

Alexion joins EURORDIS, NORD and medical communities to observe Rare Disease Day 2011

EcoNugenics introduces CIRCUTOL Cardiovascular Health Support

EcoNugenics introduces CIRCUTOL Cardiovascular Health Support

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Preclinical data of Zalicus sodium channel compound published in journal PAIN

Preclinical data of Zalicus sodium channel compound published in journal PAIN

U.S.-Chile collaborate to study new long-acting local anesthetic derived from algae

U.S.-Chile collaborate to study new long-acting local anesthetic derived from algae

AMAG fourth quarter total revenues increase to $17.2 million

AMAG fourth quarter total revenues increase to $17.2 million

Unigene accelerates UGP281 anorexigenic peptide to treat obese patients

Unigene accelerates UGP281 anorexigenic peptide to treat obese patients

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

Takeda submits NDA to FDA for fixed-dose combination of azilsartan medoxomil plus CLD to treat hypertension

EpiCept 2010 fourth quarter net loss is $0.06 per share

EpiCept 2010 fourth quarter net loss is $0.06 per share

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

Novo Nordisk submits rFXIII BLA to FDA for treatment of inherited bleeding disorder

Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys

Pretreatment with FDA-approved drug allows successful pregnancies in radiation-exposed rhesus monkeys

Scientists receive HHS grant to investigate DSC127 in treatment of skin injuries linked with radiation exposure

Scientists receive HHS grant to investigate DSC127 in treatment of skin injuries linked with radiation exposure

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

Research: Drug developed for controlling cholesterol synthesis can kill human breast cancer cells

Research: Drug developed for controlling cholesterol synthesis can kill human breast cancer cells

Researcher finds antibiotic in Eastern Red Cedar tree effective against MRSA

Researcher finds antibiotic in Eastern Red Cedar tree effective against MRSA

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.